Springfusor versus standard of care in administration of magnesium sulphate

Not Applicable

• Conditions: Pregnancy and Childbirth; Preeclampsia, eclampsia

• Registration Number: PACTR201712002887266

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-12-18
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 482

Inclusion Criteria

1.Pregnant women 20+ weeks of gestation or delivered within 24 hours,
2. diagnosed with preeclampsia and eclampsia i.e. have a raised blood pressure (systolic of >140 mmHg and diastolic > 90mmHg), proteinuria >1+.
3. Present within the study period
4. consent to participate in the study.

Exclusion Criteria

1. Had received magnesium sulphate 24 hours prior to admission,
2) has known allergy to magnesium sulphate
3) elevated serum creatinine (>1.2 mg/dl).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
¿Acceptability of Springfusor for administration of magnesium sulphate

Secondary Outcome Measures

Name	Time	Method
rate of complications;Level of pain;Discontinuation